Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02302690
Other study ID # CRIG-COL-01
Secondary ID
Status Completed
Phase N/A
First received November 25, 2014
Last updated December 12, 2017
Start date November 2014
Est. completion date June 2017

Study information

Verified date December 2017
Source Genethon
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The proposed research protocol aims at addressing these points by pre-screening CN patients for their AAV serology in link with their medical history and current medical status. A first objective is to assess the presence of neutralizing AAV antibodies in the serum of CN patients.


Recruitment information / eligibility

Status Completed
Enrollment 49
Est. completion date June 2017
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- The patient has a Crigler-Najjar syndrome

- The molecular diagnosis has been confirmed by UGT1A1 gene DNA sequencing

Exclusion criteria:

- The patient is liver transplanted

- The patient is suffering from severe associated pathologies precluding further enrolment in a future interventional clinical study

Study Design


Intervention

Biological:
Blood sample for immunology


Locations

Country Name City State
France Hopital Antoine Béclère Clamart

Sponsors (1)

Lead Sponsor Collaborator
Genethon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary To assess the presence of neutralizing AAV antibodies in the serum of CN patients 1 day visit
See also
  Status Clinical Trial Phase
Completed NCT02051049 - Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001)
Completed NCT01765283 - Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) Phase 1/Phase 2
Recruiting NCT02356978 - New Phototherapy Device to Treat Patients With Crigler-Najjar Disease N/A